Evidence map›Paper›PMID 36249342›Full record

ReviewFrontiers in allergy2022

Immediate hypersensitivity to COVID-19 vaccines: Focus on biological diagnosis.

Pascale Nicaise-Roland, Vanessa Granger, Angèle Soria, Annick Barbaud, Marc Pallardy, Sylvie Chollet-Martin, Luc de Chaisemartin

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Pascale Nicaise-RolandService d'Immunologie Biologique, Hôpital Bichat, DMU BIOGÉM, APHP, Paris, France.
Vanessa GrangerService d'Immunologie Biologique, Hôpital Bichat, DMU BIOGÉM, APHP, Paris, France.
Angèle SoriaDépartement de Dermatologie et Allergologie, Sorbonne Université, Hôpital Tenon, Paris, France.
Annick BarbaudDépartement de Dermatologie et Allergologie, Sorbonne Université, INSERM, Institut Pierre Louis D'Epidémiologie et de Santé Publique, AP-HP. Sorbonne Université, Hôpital Tenon, Paris, France.
Marc PallardyUniversité Paris-Saclay, Inserm, Inflammation Microbiome Immunosurveillance, Orsay, France.
Sylvie Chollet-MartinService d'Immunologie Biologique, Hôpital Bichat, DMU BIOGÉM, APHP, Paris, France.
Luc de ChaisemartinService d'Immunologie Biologique, Hôpital Bichat, DMU BIOGÉM, APHP, Paris, France.
Assistance Publique – Hôpitaux de Paris · FRUniversité Paris-Saclay · FRHôpital Tenon · FRSorbonne Université · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Soon after the release of the new anti-COVID mRNA vaccines, reports came in from the US and the UK of anaphylactic reactions. Fueled by the necessary caution toward these new vaccine platforms, these reports had a great impact and were largely commented upon in the scientific literature and global media. The current estimated frequency is of 5 cases per million doses. Very little biological data are presented in the literature to support the anaphylaxis diagnosis in these patients in addition to skin tests. Allergic reactions to vaccines are rare and mostly due to vaccine excipient. Therefore, the poly-ethylene-glycol (PEG) present in both mRNA formulation, and already known to be immunogenic, was soon suspected to be the potential culprit. Several hypersensitivity mechanisms to PEG or to other vaccine components can be suspected, even if the classical IgE-dependent anaphylaxis seems to be one of the most plausible candidates. In the early 2022, the international guidelines recommended to perform skin prick tests and basophil activation tests (BAT) in people experiencing allergic reaction to the first dose of COVID-19 vaccine or with a history of PEG allergy. The aim of this review is to discuss the main potential mechanisms of immediate allergy to COVID19 vaccines based on published data, together with the various techniques used to confirm or not sensitization to one component.

Indexed as

anaphylaxisbasophil activation testcomplementCOVID-19 vaccineIgE

Identifiers

PMID36249342
PMCPMC9561365
OpenAlexW4298145205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.